X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ADCOCK INGRAM
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
ADCOCK INGRAM
Jun-14
VENUS REMEDIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs218381-   
Low Rs82275-   
Sales per share (Unadj.) Rs365.6113.4-  
Earnings per share (Unadj.) Rs1.5-28.6-  
Cash flow per share (Unadj.) Rs37.9-23.7-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.589.0-  
Shares outstanding (eoy) m11.44168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.42.9 14.2%   
Avg P/E ratio x101.0-11.5 -879.4%  
P/CF ratio (eoy) x4.0-13.9 -28.6%  
Price / Book Value ratio x0.43.7 10.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,71755,398 3.1%   
No. of employees `0001.04.3 23.8%   
Total wages/salary Rs m3243,477 9.3%   
Avg. sales/employee Rs Th4,100.74,459.9 91.9%   
Avg. wages/employee Rs Th318.0809.9 39.3%   
Avg. net profit/employee Rs Th16.7-1,123.8 -1.5%   
INCOME DATA
Net Sales Rs m4,18319,146 21.8%  
Other income Rs m20134 15.0%   
Total revenues Rs m4,20319,280 21.8%   
Gross profit Rs m812-3,318 -24.5%  
Depreciation Rs m417826 50.4%   
Interest Rs m380519 73.2%   
Profit before tax Rs m35-4,529 -0.8%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m18283 6.4%   
Profit after tax Rs m17-4,824 -0.4%  
Gross profit margin %19.4-17.3 -112.0%  
Effective tax rate %51.6-6.2 -825.3%   
Net profit margin %0.4-25.2 -1.6%  
BALANCE SHEET DATA
Current assets Rs m2,77114,023 19.8%   
Current liabilities Rs m1,9317,890 24.5%   
Net working cap to sales %20.132.0 62.6%  
Current ratio x1.41.8 80.7%  
Inventory Days Days125111 112.7%  
Debtors Days Days54124 43.4%  
Net fixed assets Rs m5,3288,174 65.2%   
Share capital Rs m11489 128.7%   
"Free" reserves Rs m4,1770-   
Net worth Rs m4,37615,028 29.1%   
Long term debt Rs m1,9115,281 36.2%   
Total assets Rs m8,42828,389 29.7%  
Interest coverage x1.1-7.7 -14.1%   
Debt to equity ratio x0.40.4 124.2%  
Sales to assets ratio x0.50.7 73.6%   
Return on assets %4.7-15.2 -31.0%  
Return on equity %0.4-32.1 -1.2%  
Return on capital %6.6-19.8 -33.3%  
Exports to sales %00-   
Imports to sales %20.50-   
Net fx Rs m-8580-   
CASH FLOW
From Operations Rs m4691,634 28.7%  
From Investments Rs m29-502 -5.8%  
From Financial Activity Rs m-4644,793 -9.7%  
Net Cashflow Rs m355,925 0.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.26 Rs / ZAR

Compare VENUS REMEDIES With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: FULFORD INDIA  CADILA HEALTHCARE  WYETH LTD  DIVIS LABORATORIES  J.B.CHEMICALS  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 19, 2018 03:33 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS